TIDMC4XD
RNS Number : 2886T
C4X Discovery Holdings PLC
13 November 2019
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT
FOR PUBLICATION, DISTRIBUTION OR RELEASE, PUBLICATION OR
DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO
OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC
OF SOUTH AFRICA, NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH
SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION
IS CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL
THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
C4X Discovery Holdings plc
("C4XD" or the "Company")
Result of General Meeting and Open Offer
and
Issue of Equity
C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that at the General Meeting held
earlier today in connection with the Company's Placing,
Subscription and Open Offer, details of which were announced on 24
October 2019, all resolutions put to shareholders were duly
passed.
The Company also announces that it has received valid
acceptances in respect of 3,907,141 Open Offer Shares from Eligible
Shareholders, including applications under the Excess Application
Facility. This represents approximately 60.85 per cent. of the
6,421,404 Open Offer Shares offered.
Following the passing of the resolutions at the General Meeting,
and conditional on First Admission and Second Admission, the
Company has raised GBP7.59 million (before expenses) in aggregate
through the Placing, Subscription and Open Offer.
Applications have been made for the 46,466,667 Placing Shares,
200,000 Subscription Shares and the 3,907,141 Open Offer Shares to
be admitted to trading on AIM. It is expected that First Admission
of 25,143,330 EIS/VCT Shares will take place at 8.00 a.m. on 14
November 2019 and Second Admission of 21,323,337 General Placing
Shares, 200,000 Subscription Shares and 3,907,141 Open Offer Shares
will take place at 8.00 a.m. on 15 November 2019. The Placing
Shares, Subscription Shares and Open Offer Shares will rank pari
passu with the Existing Ordinary Shares.
Following Second Admission, the Company's issued share capital
will consist of 108,366,444 Ordinary Shares. There are no Ordinary
Shares held in treasury. Therefore, in accordance with the FCA's
Disclosure and Transparency Rule 5.6.1, the Company confirms that
as at 15 November 2019, the total number of voting rights in the
Company will be 108,366,444. Following Second Admission, this
figure may be used by shareholders as the denominator for the
calculations by which they determine whether they are required to
notify their interest in, or a change to their interest in, C4XD
under the Disclosure Guidance and Transparency Rules.
The capitalised terms used in this announcement have the meaning
as defined in the announcement published by the Company at 7 a.m.
on 24 October 2019 unless otherwise stated.
Market Abuse Regulation:
This announcement is released by C4X Discovery Holdings plc and
contains inside information for the purposes of the Market Abuse
Regulation (EU) 596/2014 ("MAR") and is disclosed in accordance
with the Company's obligations under Article 17 of MAR.
The person responsible for arranging the release of this
information is Clive Dix, CEO of the Company.
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Chris Gardner 0203 709 5700
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive
Drug Discovery engine by using cutting-edge technologies and
expertise to efficiently deliver best-in-class small-molecule
medicines to clinical partners for the benefit of patients. The
Company's business model focuses on replenishing big pharma
discovery pipelines and driving returns through revenue generating
pre-clinical licensing deals. In 2018, C4XD successfully
out-licensed a pre-clinical programme in addictive disorders to
Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies
across the Drug Discovery process and accesses further innovative
capabilities and expertise through its growing network of partners.
The Company is actively advancing its diverse pre-clinical
discovery portfolio which is focused on inflammation,
neurodegeneration and oncology (including immuno-oncology).
Opportunities to maximise value from the portfolio are proactively
driven by C4XD's commercial division. The Company is led by a
highly experienced management team and Board who have delivered
significant value creation within the healthcare sector.
For additional information please go to:
www.c4xdiscovery.com
IMPORTANT NOTICES
Panmure Gordon (UK) Limited, which is authorised and regulated
in the United Kingdom by the Financial Conduct Authority (the
"FCA"), is acting as Nominated Adviser and broker to the Company
for the purposes of the AIM Rules for Companies and the AIM Rules
for Nominated Advisers in connection with the Placing and is not
acting for, and will not be responsible to, any person other than
the Company for providing the protections afforded to customers of
Panmure Gordon (UK) Limited or for advising any other person on any
transaction or arrangement referred to in this Announcement.
--ENDS----
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMGGGQGGUPBGGW
(END) Dow Jones Newswires
November 13, 2019 06:21 ET (11:21 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Aug 2024 to Sep 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Sep 2023 to Sep 2024